Proshares UltraPro NASDAQ Biotechnology
UBIO
UBIO was delisted on the 27th of March, 2020.
7 hedge funds and large institutions have $3.4M invested in Proshares UltraPro NASDAQ Biotechnology in 2017 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.
135% more call options, than puts
Call options by funds: $552K | Put options by funds: $235K
113% more capital invested
Capital invested by funds: $1.6M → $3.4M (+$1.8M)
75% more funds holding
Funds holding: 4 → 7 (+3)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.3M |
| 2 |
ACM
Avalon Capital Management
Port Of Redwood City,
California
|
+$831K |
| 3 |
Jane Street
New York
|
+$191K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$103K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
+$10.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$377K |
| 2 |
Morgan Stanley
New York
|
-$20.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
1
Tower Research Capital (TRC)
New York
| $1.28M | +$1.3M | +38,065 | New |
|
|
ACM
2
Avalon Capital Management
Port Of Redwood City,
California
| $818K | +$831K | +24,329 | New |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $649K | -$377K | -11,031 | -36% |
|
|
4
Jane Street
New York
| $527K | +$191K | +5,597 | +56% |
|
|
5
UBS Group
Zurich,
Switzerland
| $101K | +$103K | +3,003 | New |
|
|
CG
6
Cutler Group
San Francisco,
California
| $13K | +$10.2K | +300 | +300% |
|
|
7
Morgan Stanley
New York
| $10K | -$20.5K | -600 | -67% |
|
UBIO Hedge Fund Activity: Q4 2017 in Review
7 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Proshares UltraPro NASDAQ Biotechnology (UBIO) for Q4 2017, worth a combined $3.4M — up 113% from $1.6M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new UBIO positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $1.3M. The largest seller was Susquehanna International Group, cutting an estimated $377K.
- 7 institutional investors held Proshares UltraPro NASDAQ Biotechnology (UBIO) as of Q4 2017, up from 4 in Q3 2017.
- Funds reported $3.4M of Proshares UltraPro NASDAQ Biotechnology stock for Q4 2017, up 113% quarter-over-quarter.
- 3 funds opened new Proshares UltraPro NASDAQ Biotechnology positions in Q4 2017 and 0 closed out, a net change of +3 holders.
- The largest Proshares UltraPro NASDAQ Biotechnology buyer in Q4 2017 was Tower Research Capital (TRC), an estimated $1.3M added.
- The largest Proshares UltraPro NASDAQ Biotechnology seller in Q4 2017 was Susquehanna International Group, an estimated $377K sold.
Based on aggregated 13F filings for Q4 2017.